Tamer S Kaoud

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7802707/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Multiplexing the Quantitation of MAP Kinase Activities Using Differential Sensing. Journal of the American Chemical Society, 2022, 144, 4017-4025.	13.7	12
2	Biomechanical Dependence of SARS-CoV-2 Infections. ACS Applied Bio Materials, 2022, 5, 2307-2315.	4.6	1
3	Kinetic and Structural Analysis of Two Linkers in the Tautomerase Superfamily: Analysis and Implications. Biochemistry, 2021, 60, 1776-1786.	2.5	3
4	Development of 2â€2-aminospiro [pyrano[3,2–c]quinoline]-3â€2-carbonitrile derivatives as non-ATP competitive Src kinase inhibitors that suppress breast cancer cell migration and proliferation. Bioorganic Chemistry, 2021, 116, 105344.	4.1	14
5	Rapid characterization of spike variants via mammalian cell surface display. Molecular Cell, 2021, 81, 5099-5111.e8.	9.7	32
6	NO-releasing STAT3 inhibitors suppress BRAF-mutant melanoma growth. European Journal of Medicinal Chemistry, 2020, 186, 111885.	5.5	30
7	Quantification of ERK Kinase Activity in Biological Samples Using Differential Sensing. ACS Chemical Biology, 2020, 15, 83-92.	3.4	12
8	Abstract 6312: Use of differential sensing-based biosensors to quantify ERK kinase activity in complex biological samples. Cancer Research, 2020, 80, 6312-6312.	0.9	1
9	Arrestin-3 interaction with maternal embryonic leucine-zipper kinase. Cellular Signalling, 2019, 63, 109366.	3.6	12
10	JNK2 Is Required for the Tumorigenic Properties of Melanoma Cells. ACS Chemical Biology, 2019, 14, 1426-1435.	3.4	12
11	A Novel Class of Common Docking Domain Inhibitors That Prevent ERK2 Activation and Substrate Phosphorylation. ACS Chemical Biology, 2019, 14, 1183-1194.	3.4	25
12	Design, synthesis, and DNA interaction studies of furo-imidazo[3.3.3]propellane derivatives: Potential anticancer agents. Bioorganic Chemistry, 2019, 85, 585-599.	4.1	13
13	Modulating multi-functional ERK complexes by covalent targeting of a recruitment site in vivo. Nature Communications, 2019, 10, 5232.	12.8	17
14	Arrestin-3 scaffolding of the JNK3 cascade suggests a mechanism for signal amplification. Proceedings of the United States of America, 2019, 116, 810-815.	7.1	34
15	Design, synthesis and biological evaluation of fused naphthofuro[3,2-c] quinoline-6,7,12-triones and pyrano[3,2-c]quinoline-6,7,8,13-tetraones derivatives as ERK inhibitors with efficacy in BRAF-mutant melanoma. Bioorganic Chemistry, 2019, 82, 290-305.	4.1	35
16	Abstract 2172: Quantification of ERK activity in cancer cell lysates and tumor extract using differential sensing methods. , 2019, , .		0
17	Abstract 279: c-Jun N-terminal kinase is involved in an oxidative stress- and vacuole-associated cell death pathway in triple negative breast cancer. , 2019, , .		0
10	Abstract 2872: Targeting multifunctional EDK protein complexacin vive 2010		0

Abstract 3872: Targeting multi-functional ERK-protein complexes in vivo. , 2019, , .

0

#	Article	IF	CITATIONS
19	Abstract 3872: Targeting multi-functional ERK-protein complexes <i>in vivo</i> ., 2019, , .		Ο
20	Abstract 2172: Quantification of ERK activity in cancer cell lysates and tumor extract using differential sensing methods. , 2019, , .		0
21	Abstract 279: c-Jun N-terminal kinase is involved in an oxidative stress- and vacuole-associated cell death pathway in triple negative breast cancer. , 2019, , .		Ο
22	Pro-metastatic collagen lysyl hydroxylase dimer assemblies stabilized by Fe2+-binding. Nature Communications, 2018, 9, 512.	12.8	34
23	Dynamic equilibrium of eEFâ€⊋K and CaM as a regulatory logic circuit: investigations in MCF10A cells. FASEB Journal, 2018, 32, .	0.5	Ο
24	c-Jun N-terminal kinase promotes stem cell phenotype in triple-negative breast cancer through upregulation of Notch1 via activation of c-Jun. Oncogene, 2017, 36, 2599-2608.	5.9	70
25	Signal Integration at Elongation Factor 2 Kinase. Journal of Biological Chemistry, 2017, 292, 2032-2045.	3.4	15
26	Novel quinoline incorporating 1,2,4-triazole/oxime hybrids: Synthesis, molecular docking, anti-inflammatory, COX inhibition, ulceroginicity and histopathological investigations. Bioorganic Chemistry, 2017, 75, 242-259.	4.1	41
27	Serotonin Analogues as Inhibitors of Breast Cancer Cell Growth. ACS Medicinal Chemistry Letters, 2017, 8, 1072-1076.	2.8	21
28	Local destabilization, rigid body, and fuzzy docking facilitate the phosphorylation of the transcription factor Ets-1 by the mitogen-activated protein kinase ERK2. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E6287-E6296.	7.1	22
29	Kinetic and structural characterization of a cis -3-Chloroacrylic acid dehalogenase homologue in Pseudomonas sp. UW4: A potential step between subgroups in the tautomerase superfamily. Archives of Biochemistry and Biophysics, 2017, 636, 50-56.	3.0	9
30	Abstract 1899: MKK4/JNK2 down-regulation in NSCLC suppresses tumor growth and metastasis. , 2017, , .		1
31	A c-Jun N-terminal kinase inhibitor, JNK-IN-8, sensitizes triple negative breast cancer cells to lapatinib. Oncotarget, 2017, 8, 104894-104912.	1.8	28
32	Novel 1,3,4-oxadiazole/oxime hybrids: Synthesis, docking studies and investigation of anti-inflammatory, ulcerogenic liability and analgesic activities. Bioorganic Chemistry, 2016, 69, 48-63.	4.1	34
33	Peptide mini-scaffold facilitates JNK3 activation in cells. Scientific Reports, 2016, 6, 21025.	3.3	50
34	Abstract A17: TRPM7 kinase domain is involved in breast tumor cell metastasis. , 2016, , .		0
35	Abstract 3771: Discovery of a covalent inhibitor of ERK docking-interactions that inhibits A375 melanoma cells proliferation. , 2016, , .		0
36	Abstract 3774: KD06 is a novel anti-cancer drug that causes cell death in triple-negative breast cancer cell lines and tumor xenografts. , 2016, , .		0

Tamer S Kaoud

#	Article	IF	CITATIONS
37	Structural and Dynamic Features of F-recruitment Site Driven Substrate Phosphorylation by ERK2. Scientific Reports, 2015, 5, 11127.	3.3	19
38	Arrestinâ€3â€Dependent Activation of câ€Jun Nâ€Terminal Kinases (JNKs). Current Protocols in Pharmacology, 2015, 68, 2.12.1-2.12.26.	4.0	11
39	Quantification of a Pharmacodynamic ERK End Point in Melanoma Cell Lysates: Toward Personalized Precision Medicine. ACS Medicinal Chemistry Letters, 2015, 6, 47-52.	2.8	14
40	Targeting the transient receptor potentialâ€melastatinâ€like 7 (Trpm7) kinase domain with the first inhibitor, inhibited breast cancer cell migration, invasion and tumor metastasis FASEB Journal, 2015, 29, 1021.9.	0.5	0
41	Selfâ€phosphorylation Primes JNK2 For Activation by MKK4 in Glioblastoma and Nonâ€small Cell Lung Carcinoma FASEB Journal, 2015, 29, 724.16.	0.5	0
42	Abstract 1945: Self-phosphorylation primes JNK2 for activation by MKK4 in glioblastoma and non-small cell lung carcinoma. , 2015, , .		0
43	Abstract 3569: Inhibition of the TRPM7 kinase domain inhibits breast cancer cell migration and invasion and tumor metastasis. , 2015, , .		0
44	Abstract 1505: Suppression of triple-negative breast cancer tumorigenesis by targeting cancer stem cells through JNK/Notch1 signaling inhibition. , 2015, , .		1
45	Abstract 3648: A high-throughput fluorescence anisotropy screening for discovery of inhibitors that target the D-recruitment site of ERK in vitro and in cells. , 2015, , .		0
46	Abstract 1941: Distinct roles of c-Jun N-terminal kinase (JNK) isoforms in skin cancer. , 2015, , .		0
47	Novel 1-[4-(Aminosulfonyl)phenyl]-1H-1,2,4-triazole derivatives with remarkable selective COX-2 inhibition: Design, synthesis, molecular docking, anti-inflammatory and ulcerogenicity studies. European Journal of Medicinal Chemistry, 2014, 83, 398-408.	5.5	40
48	Reversible Covalent Inhibition of eEFâ€2K by Carbonitriles. ChemBioChem, 2014, 15, 2435-2442.	2.6	23
49	Propyphenazone-Based Analogues as Prodrugs and Selective Cyclooxygenase-2 Inhibitors. ACS Medicinal Chemistry Letters, 2014, 5, 983-988.	2.8	12
50	Differential Sensing of MAP Kinases Using SOXâ€Peptides. Angewandte Chemie - International Edition, 2014, 53, 14064-14068.	13.8	37
51	Modulation of eukaryotic elongation factor 2 kinase activity via phosphorylation on Serâ€500 (773.1). FASEB Journal, 2014, 28, 773.1.	0.5	0
52	Investigating proximityâ€mediated catalysis by a protein kinase: how docking affects MAPK specificity and processivity (802.16). FASEB Journal, 2014, 28, 802.16.	0.5	0
53	Abstract 3227: JNK2 oligomerization regulates its activation through non-canonical pathways. , 2014, , .		0
54	Abstract 5462: Antiproliferative and cytotoxic activities of 5-(nonyloxy)tryptamine derivatives in breast cancer cells. , 2014, , .		0

#	Article	IF	CITATIONS
55	Abstract 513: Investigating stress-response pathways in pancreatic cancer cells using novel PERK inhibitors. , 2014, , .		0
56	Abstract 2722: Suppression of breast cancer cell migration by novel inhibitors that target transient receptor potential-melastatin-like 7 (Trpm7) kinase activity. , 2014, , .		0
57	Abstract 750: JNK-IN-8: a novel covalent inhibitor targeting JNK signaling in triple-negative breast cancer. , 2014, , .		Ο
58	In-Situ Generation of Differential Sensors that Fingerprint Kinases and the Cellular Response to Their Expression. Journal of the American Chemical Society, 2013, 135, 14814-14820.	13.7	69
59	A Fluorescenceâ€Based Assay for p38α Recruitment Site Binders: Identification of Rooperol as a Novel p38α Kinase Inhibitor. ChemBioChem, 2013, 14, 66-71.	2.6	13
60	High-throughput Database Search and Large-scale Negative Polarity Liquid Chromatography–Tandem Mass Spectrometry with Ultraviolet Photodissociation for Complex Proteomic Samples. Molecular and Cellular Proteomics, 2013, 12, 2604-2614.	3.8	33
61	Arrestin-3 Binds c-Jun N-terminal Kinase 1 (JNK1) and JNK2 and Facilitates the Activation of These Ubiquitous JNK Isoforms in Cells via Scaffolding. Journal of Biological Chemistry, 2013, 288, 37332-37342.	3.4	62
62	JNK3 Enzyme Binding to Arrestin-3 Differentially Affects the Recruitment of Upstream Mitogen-activated Protein (MAP) Kinase Kinases. Journal of Biological Chemistry, 2013, 288, 28535-28547.	3.4	48
63	Abstract 2222: Analysis of the autophosphorylation-induced calcium-independent activity of human elongation factor 2 kinase (eEF-2K) - a therapeutic target for breast cancer , 2013, , .		0
64	Arrestinâ€3 binding to JNK1alpha1/JNK2alpha2: modulation of JNK1 and JNK2 activity via scaffolding. FASEB Journal, 2013, 27, 1042.6.	0.5	0
65	Abstract 4551: Identification of TRPM7 kinase inhibitors , 2013, , .		Ο
66	Abstract 3241: Preclinical development of JNK-targeted therapy for triple-negative breast cancer , 2013, , .		0
67	Evidence of the Regulation of JNK2 through Oligomerization. FASEB Journal, 2013, 27, 789.22.	0.5	Ο
68	JNK3 binding to arrestinâ€3 differentially affects recruitment of upstream MAP kinase kinases. FASEB Journal, 2013, 27, 1042.4.	0.5	0
69	Computational Insights for the Discovery of Non-ATP Competitive Inhibitors of MAP Kinases. Current Pharmaceutical Design, 2012, 18, 1173-1185.	1.9	19
70	Manipulating JNK Signaling with (â^')-Zuonin A. ACS Chemical Biology, 2012, 7, 1873-1883.	3.4	20
71	Calcium/Calmodulin Stimulates the Autophosphorylation of Elongation Factor 2 Kinase on Thr-348 and Ser-500 To Regulate Its Activity and Calcium Dependence. Biochemistry, 2012, 51, 2232-2245.	2.5	56
72	From in Silico Discovery to Intracellular Activity: Targeting JNK–Protein Interactions with Small Molecules. ACS Medicinal Chemistry Letters, 2012, 3, 721-725.	2.8	25

#	Article	IF	CITATIONS
73	Targeted Silencing of Elongation Factor 2 Kinase Suppresses Growth and Sensitizes Tumors to Doxorubicin in an Orthotopic Model of Breast Cancer. PLoS ONE, 2012, 7, e41171.	2.5	95
74	Investigating the Kinetic Mechanism of Inhibition of Elongation Factor 2 Kinase by NH125: Evidence of a Common in Vitro Artifact. Biochemistry, 2012, 51, 2100-2112.	2.5	52
75	Chargeâ€5iteâ€Dependent Dissociation of Hydrogenâ€Rich Radical Peptide Cations upon Vacuum UV Photoexcitation. Chemistry - A European Journal, 2012, 18, 5374-5383.	3.3	19
76	Computational Insights for the Discovery of Non-ATP Competitive Inhibitors of MAP Kinases. Current Drug Metabolism, 2012, 18, 1173-1185.	1.2	1
77	Nonâ€visual arrestins function as simple scaffolds assembling the MKK4–JNK3a2 signaling complex. FASEB Journal, 2012, 26, 761.5.	0.5	0
78	Abstract 4776: From in-silico screening to anti-cancer activity: The discovery of a potent inhibitor targeting the JNK-JIP interaction. , 2012, , .		0
79	Examining Docking Interactions on ERK2 with Modular Peptide Substrates. Biochemistry, 2011, 50, 9500-9510.	2.5	34
80	Nonvisual Arrestins Function as Simple Scaffolds Assembling the MKK4–JNK3α2 Signaling Complex. Biochemistry, 2011, 50, 10520-10529.	2.5	61
81	Development of JNK2-Selective Peptide Inhibitors That Inhibit Breast Cancer Cell Migration. ACS Chemical Biology, 2011, 6, 658-666.	3.4	44
82	Activated ERK2 Is a Monomer in Vitro with or without Divalent Cations and When Complexed to the Cytoplasmic Scaffold PEA-15. Biochemistry, 2011, 50, 4568-4578.	2.5	38
83	Solution NMR Insights into Docking Interactions Involving Inactive ERK2. Biochemistry, 2011, 50, 3660-3672.	2.5	39
84	Understanding the Specificity of a Docking Interaction between JNK1 and the Scaffolding Protein JIP1. Journal of Physical Chemistry B, 2011, 115, 1491-1502.	2.6	34
85	193â€nm photodissociation of singly and multiply charged peptide anions for acidic proteome characterization. Proteomics, 2011, 11, 1329-1334.	2.2	70
86	A Model of a MAPK•Substrate Complex in an Active Conformation: A Computational and Experimental Approach. PLoS ONE, 2011, 6, e18594.	2.5	20
87	Fluorescent Peptide Assays for Protein Kinases. Current Protocols in Molecular Biology, 2010, 91, Unit 18.17.	2.9	7
88	Synthesis and biological evaluation of p38α kinase-targeting dialkynylimidazoles. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 6293-6297.	2.2	23